RU93058654A - Способ определения полезности пролекарств, превращающихся печенью, их применение в терапии, пролекарство - Google Patents

Способ определения полезности пролекарств, превращающихся печенью, их применение в терапии, пролекарство

Info

Publication number
RU93058654A
RU93058654A RU93058654/14A RU93058654A RU93058654A RU 93058654 A RU93058654 A RU 93058654A RU 93058654/14 A RU93058654/14 A RU 93058654/14A RU 93058654 A RU93058654 A RU 93058654A RU 93058654 A RU93058654 A RU 93058654A
Authority
RU
Russia
Prior art keywords
usefulness
cookies
therapy
medicine
determining
Prior art date
Application number
RU93058654/14A
Other languages
English (en)
Other versions
RU2126255C1 (ru
Inventor
Ченг Юнг-Чи
Чанг Чин-Ненг
Original Assignee
Йель Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йель Юниверсити filed Critical Йель Юниверсити
Publication of RU93058654A publication Critical patent/RU93058654A/ru
Application granted granted Critical
Publication of RU2126255C1 publication Critical patent/RU2126255C1/ru

Links

Claims (1)

  1. Предложен способ установления полезности пролекарства для лечения заболевания. Пролекарство приемлемо, если оно превращается в клетках печени альдегидоксидазой в активное лекарство или метаболит. Показано, что пролекарства также эффективны при лечении заболеваний, как и сами лекарства, причем оказывают многочисленные благоприятные воздействия и лишены многих побочных эффектов. Предложены также способы лечения раковых заболеваний 5-иод-2-пиримидинондезоксирибозой и 5-фтор-2-пиримидиноном.
RU93058654A 1991-05-15 1992-05-15 Способ получения противоопухолевого эффекта у млекопитающих RU2126255C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US701,462 1985-02-14
US70146291A 1991-05-15 1991-05-15
US82947492A 1992-02-03 1992-02-03
US829,474 1992-02-03

Publications (2)

Publication Number Publication Date
RU93058654A true RU93058654A (ru) 1996-11-10
RU2126255C1 RU2126255C1 (ru) 1999-02-20

Family

ID=27106792

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93058654A RU2126255C1 (ru) 1991-05-15 1992-05-15 Способ получения противоопухолевого эффекта у млекопитающих

Country Status (13)

Country Link
US (1) US5728684A (ru)
EP (1) EP0586523A4 (ru)
JP (1) JPH06507902A (ru)
KR (1) KR100245252B1 (ru)
AU (1) AU673803B2 (ru)
BG (1) BG98217A (ru)
CA (1) CA2103050A1 (ru)
HU (1) HUT67392A (ru)
IE (1) IE921581A1 (ru)
IL (1) IL101879A (ru)
NO (2) NO306850B1 (ru)
RU (1) RU2126255C1 (ru)
WO (1) WO1992020816A1 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9600847D0 (en) 1996-01-16 1996-03-20 Smithkline Beecham Plc Pharmaceuticals
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1109580A4 (en) * 1998-09-04 2004-05-26 Viropharma Inc METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
ES2250112T3 (es) 1999-03-08 2006-04-16 Medicure Inc. Analogos de piridoxal para el tratamiento de trastornos causados por carencia de vitamina b6.
WO2001003745A2 (en) * 1999-07-09 2001-01-18 Board Of Regents Of University Of Nebraska Therapy and diagnosis of colorectal cancer with radiopharmaceuticals
CA2376029A1 (en) 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
ATE293119T1 (de) 2000-02-29 2005-04-15 Medicure Int Inc Cardioprotektive phosphonate
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU784840B2 (en) 2000-03-28 2006-07-06 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
EP1299358B1 (en) 2000-07-07 2007-06-13 Medicure International Inc. Pyridoxine and pyridoxal analogues as cardiovascular therapeutics
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US8207142B2 (en) * 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
US7015022B2 (en) * 2002-06-07 2006-03-21 University Of Medicine & Dentistry Of New Jersey Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
AU2005259735A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
AU2005304220A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
KR20080023680A (ko) 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체
AU2006317440A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
RU2527457C2 (ru) * 2012-09-27 2014-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
WO2016057699A1 (en) 2014-10-07 2016-04-14 Kinsella Timothy J METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPdR)
US11654157B2 (en) 2017-01-09 2023-05-23 Shuttle Pharmaceuticals, Inc. Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
WO2018148580A1 (en) * 2017-02-09 2018-08-16 Perfect Daylight Limited Methods for autism spectrum disorder pharmacotherapy
US20220296926A1 (en) 2019-07-31 2022-09-22 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895937A (en) * 1982-01-05 1990-01-23 The Research Foundation Of State University Of New York 5-ioso-2-pyrimidinone nucleoside
US4782142A (en) * 1982-01-05 1988-11-01 The Research Foundation Of State University Of New York Novel 5-substituted 2-pyrimidinone nucleosides and methods of use
US4468384A (en) * 1982-01-05 1984-08-28 The Research Foundation Of State University Of New York Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides
FI881216A (fi) * 1987-03-16 1988-09-17 Wellcome Found Terapeutiska nukleosider.
US4942226A (en) * 1988-12-29 1990-07-17 Merck & Co., Inc. Halogenated pyrimidine nucleosides and their derivatives
ES2111569T3 (es) * 1990-07-19 1998-03-16 Wellcome Found Inactivadores de enzimas.
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations

Similar Documents

Publication Publication Date Title
RU93058654A (ru) Способ определения полезности пролекарств, превращающихся печенью, их применение в терапии, пролекарство
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DE3579068D1 (de) Arzneimittelenthaltende matrizen fuer einfuehrungen in zonen mit cellularen lesionen.
ES2058592T3 (es) El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.
DE69815122T2 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
PT730864E (pt) Medicamento para tratar doencas inflamatorias cardiacas
DE3382641T2 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
NL188078B (nl) Farmaceutisch preparaat voor de behandeling van hartarrhytmieen en myocardiale aandoeningen.
ATE122885T1 (de) Mittel zur behandlung von herzerkrankungen.
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
DK0559145T3 (da) Lægemiddel til truende abort
RU94011321A (ru) Способ профилактики и лечения заболеваний кожи
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
FR2353544A1 (fr) Esters benzyliques et esters apparentes d'acides 6,11-dihydrodibenz(b,e)oxepine-acetiques, leur procede de preparation et leur application therapeutique
NO308195B1 (no) Anvendelse av benzydamin til fremstilling av et legemiddel ved behandling av patologiske tilstander forÕrsaket av TNF
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
冯如珍 RELIEF OF OESOPHAGEAL CARCINOMATOUS OBSTRUCTION BY ACUPUNCTURE
FR2645747B1 (fr) Nouvelles compositions pharmaceutiques, leur procede d'obtention et leur emploi en therapeutique tumorale